Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Public ClinicalTrials.gov record NCT04330664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2
Study identification
- NCT ID
- NCT04330664
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Enrollment
- 86 participants
Conditions and interventions
Interventions
- MRTX849 Drug
- TNO155 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 6, 2020
- Primary completion
- Jul 28, 2022
- Completion
- Feb 23, 2025
- Last update posted
- Apr 3, 2025
2020 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 002-805 | Los Angeles | California | 90095 | — |
| Local Institution - 002-803 | Orange | California | 92868 | — |
| Local Institution - 002-828 | Chicago | Illinois | 60611 | — |
| Local Institution - 002-942 | Wichita | Kansas | 67214 | — |
| Local Institution - 002-804 | Boston | Massachusetts | 02114 | — |
| Local Institution - 002-808 | Boston | Massachusetts | 02215 | — |
| Local Institution - 002-811 | Novi | Michigan | 48377 | — |
| Local Institution - 002-809 D | City of Saint Peters | Missouri | 63376 | — |
| Local Institution - 002-809 B | Creve Coeur | Missouri | 63141 | — |
| Local Institution - 002-809 A | St Louis | Missouri | 63110 | — |
| Local Institution - 002-809 C | St Louis | Missouri | 63129 | — |
| Local Institution - 002-809 | St Louis | Missouri | 63130 | — |
| Local Institution - 002-809 E | St Louis | Missouri | 63136 | — |
| Local Institution - 002-813 | New York | New York | 10016 | — |
| Local Institution - 002-806 | New York | New York | 10065 | — |
| Local Institution - 002-801 | San Antonio | Texas | 78229 | — |
| Local Institution - 002-810 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04330664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04330664 live on ClinicalTrials.gov.